For years, the cardiovascular community has relied on the efficacy of low-dose rivaroxaban (Xarelto) to provide cardioprotective benefits to patients with coronary and peripheral artery disease. However, a major international clinical trial has revealed that this success does not translate to the high-risk population of patients with advanced chronic kidney disease (CKD).
The results of the TRACK trial, recently published in JAMA and presented at the European Renal Association Congress, serve as a stark reminder that the physiological complexities of advanced CKD require specialized therapeutic strategies rather than the simple extrapolation of findings from the general population.
Main Facts: The Failure of the TRACK Trial
The TRACK trial was designed to test whether a twice-daily 2.5 mg dose of rivaroxaban could reduce the incidence of major adverse cardiovascular events (MACE) in patients with advanced CKD. The composite primary outcome included cardiovascular death, nonfatal myocardial infarction, stroke, or peripheral artery disease-related events.
After a median follow-up of 1.7 years, the results were unequivocal: the regimen provided no clinical benefit. The rate of the composite primary endpoint was 22.6% in the rivaroxaban group compared to 20.7% in the placebo group (Hazard Ratio [HR] 1.09; 95% CI 0.87-1.36).
Perhaps more concerning than the lack of efficacy was the safety profile. Patients assigned to rivaroxaban experienced a significantly higher rate of major bleeding—8.8% compared to 6.0% in the placebo arm (HR 1.51; 95% CI 1.02-2.22). The investigators, led by Dr. Sunil Badve of the University of New South Wales Sydney, concluded that the drug failed to protect against cardiovascular death while simultaneously increasing the risk of life-threatening hemorrhage.
Chronology: From Pandemic Hurdles to Premature Termination
The trajectory of the TRACK trial was hampered by both global logistical challenges and scientific disappointment.
- Trial Initiation: The study began during the height of the COVID-19 pandemic, an environment that complicated recruitment and follow-up across its 12-country, multi-continental footprint.
- Design Ambitions: Investigators originally aimed to enroll 1,900 participants over a three-year period to achieve sufficient statistical power.
- The Interim Analysis: By August 2025, with fewer than 1,500 patients randomized, an interim analysis was performed. The data showed a lack of efficacy so profound that the trial was stopped early.
- Publication: The findings were formally presented at the European Renal Association Congress and subsequently published in JAMA, closing the book on this specific clinical inquiry while opening a new chapter of questions regarding cardiovascular management in CKD.
Supporting Data: Understanding the Cohort
The study’s demographic breakdown highlights the high-risk nature of the population studied. Researchers screened 5,979 individuals, eventually randomizing 1,458 into the study.
The cohort was composed of two distinct groups: those with CKD stage 4 or 5 who were not yet receiving kidney replacement therapy, and those who were already dialysis-dependent. The mean age of the participants was 63.2 years, with nearly 30% being women. Crucially, the population carried a heavy burden of comorbid disease:
- Diabetes: More than 75% of participants had diabetes.
- Age: Nearly half of the participants were 65 or older.
- Prior Disease: Approximately 20% had a history of coronary artery disease.
One of the significant caveats noted by the researchers was the high rate of study drug discontinuation, which reached 28.2%. While 93.3% of the participants completed the follow-up, the high dropout rate from the medication itself may have influenced the efficacy results, though it does not explain the significant increase in bleeding events.
Official Responses and Clinical Implications
The medical community has responded to the TRACK trial with a mix of resignation and a call for a strategic pivot in research design.
The Editorial Perspective
In an accompanying editorial, Dr. Nisha Bansal (University of Washington) and Dr. Wolfgang Winkelmayer (Baylor College of Medicine) addressed the "problematic" nature of applying standard cardiovascular findings to advanced CKD. They noted that the distinct biology of uremia—the accumulation of nitrogenous waste in the blood due to kidney failure—fundamentally alters how these patients experience both clotting and bleeding.
"Extrapolating findings from broader populations to advanced CKD is problematic," the authors wrote. They emphasized that the "uremic milieu" creates unique mechanisms for cardiovascular damage that anticoagulants simply do not address.
A New Understanding of Sudden Cardiac Death
Perhaps the most eye-opening data point from the trial was that 42.1% of all deaths in the cohort were classified as sudden cardiac death. This figure challenges the traditional hypothesis that the primary cause of mortality in these patients is thrombotic (blood-clotting related). If the mortality is being driven by arrhythmias or metabolic instability rather than arterial blockage, it explains why an anticoagulant like rivaroxaban would fail to move the needle on mortality.
"This observation calls for a strategic pivot in the design of future trials," Bansal and Winkelmayer noted. They suggest that future research must move beyond simple anticoagulation and focus on the metabolic, inflammatory, and electrophysiological pathways that actually govern heart health in patients with kidney failure.
Implications for Future Research
The failure of TRACK does not mean the end of cardiovascular research in CKD, but it does signal that the field needs a more nuanced approach.
1. Identifying the Right Candidates
The trial’s authors and editorialists suggest that the "one-size-fits-all" approach to cardiovascular prevention in CKD is defunct. Future studies may need to isolate specific subsets of patients—such as those with established, symptomatic cardiovascular disease—to determine if any benefit can be derived from anti-thrombotic therapy.
2. Alternative Strategies
Because anticoagulation comes with an inherent bleeding risk, researchers are now looking at alternative oral anticoagulant strategies or perhaps non-anticoagulant therapies that focus on the specific inflammatory processes associated with CKD.
3. The Unmet Need
The burden of cardiovascular disease in advanced CKD remains catastrophic. With nearly half of all deaths in this population attributable to cardiovascular causes, the clinical community is under immense pressure to find effective interventions. The TRACK trial has cleared the path by eliminating an ineffective, potentially harmful option, forcing the medical community to return to the drawing board.
Conclusion
The TRACK trial is a definitive "negative" study, yet it is arguably one of the most important trials in recent nephrology history. By proving that a therapy validated in the general population can be ineffective—and even dangerous—in patients with advanced kidney disease, it underscores the necessity of clinical trials that specifically enroll this vulnerable group.
As clinicians navigate the care of patients with stage 4 or 5 CKD, the takeaway is clear: do not assume that cardiovascular guidelines for the general population are safe or effective for those with renal failure. The road forward lies in understanding the unique pathophysiology of the uremic heart and developing interventions tailored to its specific, life-threatening demands. While the door to anticoagulation is not closed, it is now firmly shut on the current standard-of-care approach for this high-risk population.
